Profectus BioSciences, Inc. Announces Initiation of Clinical Trial of IL-12 Enhanced Therapeutic HIV DNA Vaccine Delivered Using Electroporation
1/5/2011 9:39:51 AM
(BUSINESS WIRE)--Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, and the AIDS Clinical Trials Group (ACTG) announced today the initiation of a phase 1 study of Profectus’ multi-antigen HIV plasmid DNA (pDNA) vaccine administered with various doses of GENEVAX™ interleukin-12 (IL-12) pDNA adjuvant and delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems. The multi-center study is being sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is being conducted by the NIAID-funded ACTG under a protocol designated A5281.